Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has signed a distributor agreement with the Research Institute for Liver Diseases (RILD) in Shanghai, People’s Republic of China.

Mr. John DiBella, vice president for marketing and sales for Simulations Plus, said, “We’re very pleased to be working with the RILD to offer in silico consulting services using our various software programs in support of RILD’s in vitro experimental systems to its customers in China. Dr. Zhuohan Hu, President and CEO of RILD, is highly respected within the pharmaceutical industry in China, and we look forward to leveraging his connections with researchers at regulatory agencies and local companies to continue penetrating this growing market. We expect this new dealership to help promote our consulting services in the areas of drug absorption, toxicity, metabolism, and drug-drug interactions.”